Single-arm Open-label Trial to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BI 3000202 in Adult Patients With Selected Type 1 Interferonopathies
Latest Information Update: 07 Apr 2025
At a glance
- Drugs BI 3000202 (Primary)
- Indications Immunological disorders
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 21 Mar 2025 New trial record
- 19 Mar 2025 Planned initiation date changed from 28 Mar 2025 to 4 Apr 2025.